Last reviewed · How we verify
IBI308
IBI308 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
IBI308 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Gastric cancer, Esophageal cancer.
At a glance
| Generic name | IBI308 |
|---|---|
| Also known as | Sintilimab |
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
IBI308 is a humanized monoclonal antibody targeting programmed death receptor 1 (PD-1). By blocking PD-1, the drug prevents tumor cells from suppressing T cell-mediated immunity, allowing the immune system to recognize and attack cancer cells more effectively. This mechanism is similar to other checkpoint inhibitors and is designed to enhance endogenous anti-tumor immunity across multiple cancer types.
Approved indications
- Non-small cell lung cancer
- Gastric cancer
- Esophageal cancer
Common side effects
- Fatigue
- Decreased appetite
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Infusion-related reactions
Key clinical trials
- SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC (NA)
- Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer (PHASE3)
- Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma (PHASE2)
- Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study (PHASE2)
- Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients (PHASE2)
- Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies） (PHASE2)
- PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |